{"id":"neu2000kwl-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neu2000KWL combines NMDA receptor antagonism with free radical scavenging properties to protect neurons from ischemic and excitotoxic injury. The dual mechanism targets both glutamate-mediated excitotoxicity and reactive oxygen species generation, which are key pathological processes in acute brain injury. This combination approach aims to provide superior neuroprotection compared to single-mechanism agents.","oneSentence":"Neu2000KWL is a neuroprotective agent designed to reduce excitotoxic and oxidative damage in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:57.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Traumatic brain injury"}]},"trialDetails":[{"nctId":"NCT05041010","phase":"PHASE3","title":"Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz","status":"UNKNOWN","sponsor":"GNT Pharma","startDate":"2021-12-25","conditions":"Ischemic Stroke","enrollment":496},{"nctId":"NCT04486430","phase":"PHASE2","title":"Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2017-03-02","conditions":"Stroke, Cerebral Infarction","enrollment":236},{"nctId":"NCT03651557","phase":"PHASE2","title":"Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients","status":"UNKNOWN","sponsor":"GNT Pharma","startDate":"2018-11-29","conditions":"Cardiac Arrest","enrollment":150},{"nctId":"NCT02831088","phase":"PHASE2","title":"Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)","status":"UNKNOWN","sponsor":"GNT Pharma","startDate":"2016-07","conditions":"Ischemic Stroke","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Salfaprodil for injection"],"phase":"phase_3","status":"active","brandName":"Neu2000KWL group","genericName":"Neu2000KWL group","companyName":"GNT Pharma","companyId":"gnt-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neu2000KWL is a vaccine component that induces an immune response, as indicated by its mechanism of action. It is being studied in a Phase II clinical trial for the treatment of ischemic stroke, cardiac arrest, stroke, and cerebral infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}